UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 9, 2006
Hana Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation) | 001-32626 (Commission File Number) | 32-0064979 (IRS Employer Identification No.) |
| | |
| | |
400 Oyster Point Blvd., Ste. 215, South San Francisco, CA (Address of principal executive offices) | 94080 (Zip Code) |
(650) 588-6404
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On March 9, 2006, Hana Biosciences, Inc. (the “Company”) issued a press release announcing the results of certain clinical trials of its product candidate ZensanaTM (ondansetron oral spray). The press release is attached to this Current Report as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibit is filed herewith.
| | Exhibit No. | | Description |
| | 99.1 | | Press release dated March 9, 2006. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | HANA BIOSCIENCES, INC. |
|
|
|
| Date: March 9, 2006 | By: | /s/ John P. Iparraguirre |
| |
John P. Iparraguirre Chief Financial Officer |
EXHBIT INDEX
Ex. No. | | Description |
| | | |
| 99.1 | | Press release dated March 9, 2006. |
